Axsome Therapeutics (AXSM) Non-Current Assets (2015 - 2026)

Axsome Therapeutics has reported Non-Current Assets for 12 years, with the latest figure at $102.4 million in Q1 2026.

• Quarterly Non-Current Assets changed 0.36% year-over-year to $102.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $410.3 million (up 16.23% YoY) and the FY2025 annual result came in at $100.8 million, up 20.84% from the prior year.
• Non-Current Assets rose to $102.4 million in Q1 2026 per AXSM's latest filing, from $100.8 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $103.9 million in Q3 2025 and troughed at $1.7 million in Q1 2022.
• A 5-year average of $85.2 million and a median of $85.8 million in 2022 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets surged 6675.02% in 2022, then dropped 7.58% in 2024.
• Over 5 years, Non-Current Assets stood at $85.8 million in 2022, then slipped by 2.17% to $84.0 million in 2023, then declined by 0.64% to $83.4 million in 2024, then grew by 20.84% to $100.8 million in 2025, then climbed by 1.57% to $102.4 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $102.4 million, $100.8 million, and $103.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.